Palatin Technologies Inc. research and ratings by Barron's. View PTNT revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible reset ...

Novo Nordisk has pulled ahead in the race to bring the first oral GLP-1 for obesity to market. The company announced Friday ...

The Board of Directors of Indian Bank Limited, at its meeting held today have approved the financial results of the company ...

The Board of Directors of TRF Limited, at its meeting held today have approved the financial results of the company for the ...

This report explores the top FTSE 100 shares to watch next week. The top names include the likes of IAG, IHG, and Flutter ...

Recommendation based on AMPLIFY Phase III trial which showed Calquencecombinations demonstrated statistically significant and clinically meaningfulimprovement in progression-free survival vs.

Discover AstraZeneca's Q1 2025 performance with 10% revenue growth, innovative medicines, and bold 2030 goals.

We recently published a list of Billionaire Israel Englander’s 10 Stock Picks with Huge Upside Potential. In this article, we ...

Below we take a look at what went wrong for BP last quarter. There was more bad news for BP, as it continues to see its woes ...

A 15% drop in the Amazon share price has put it on Stephen Wright’s radar. But what other growth stocks are worth considering ...

A daily rundown of the economic reports and corporate earnings that will be grabbing the market’s attention in the week ahead ...